Introducing a modern chemotherapeutic drug formulated by iron nanoparticles for the treatment of human lung cancer

In the present study, iron nanoparticles were green-synthesized using the aqueous extract of Alhagi maurorum leaf aqueous extract. The synthesized FeNPs were characterized by analytical techniques including EDX, FE-SEM, XRD, UV–vis and FT-IR. The anti-human lung cancer activity of FeNPs was evaluated using MTT assay. The nanoparticles were formed in a spherical shape in the average size of 60.11 nm. In the cellular and molecular part of the recent study, the treated cells with FeNPs were assessed by MTT assay for 48 h about the cytotoxicity and anti-human lung cancer properties on normal (HUVEC) and lung cancer cell lines i.e. HLC-1 and PC-14. The viability of malignant lung cell line reduced dose-dependently in the presence of FeNPs. The IC50 of FeNPs was 195 and 181 µg/mL against HLC-1 and PC-14 cell lines, respectively. In the antioxidant test, the IC50 of FeNPs and BHT against DPPH free radicals was 214 and 62 µg/mL, respectively. After the clinical study, iron nanoparticles containing A. maurorum leaf aqueous extract may be used to formulate a new chemotherapeutic drug or supplement to treat several types of human lung cancer.